New drug GQ1005 takes on T-DM1 in advanced HER2-Positive breast cancer
Disease control
Recruiting now
This phase 3 trial tests whether a new drug called GQ1005 works better than the current standard treatment T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. Participants have already been treated with trastuzumab and a taxane. The …
Phase: PHASE3 • Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC